



September 30, 2019
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

Announcement of Investment in Regenerative Medicine Venture Company Heartseed Inc.

Tokyo, September 30, 2019 – Gene Techno Science Co., Ltd. (TSE Mothers: 4584 “GTS”) announced our investment in Heartseed Inc (“Heartseed”), a venture company in regenerative medicine field as below.

1. Purpose for this investment

Heartseed is a company established in November 2015 as a venture spun out from Keio University to deliver fundamental treatment to patients with severe cardiac failure through “myocardial regenerative medicine”. Heartseed has developed technology for generating ventricular cardiomyocytes differentiated and induced from iPS cells to supply as highly purified regenerative medicine products for patients with severe cardiac failure, and is currently working toward commercialization of this product. In addition, by acquiring technologies that remove undifferentiated cells, which can be applied to other medicines than myocardial regenerative medicine, and those which can safely and efficiently produce high-quality iPS cells through the process of its research and development, Heartseed is also expected to apply these technologies for the development of other type of regenerative medicine..

GTS has been diligently promoting the new biotech business and as part of further business development, intends to explore the possibility of collaboration and synergy between two companies while to contribute to further expansion and revitalization of regenerative medicine market in Japan with the growth of Heartseed business through the equity investment in Heartseed, a promising regenerative medicine venture company,

2. Outline of counterparties to this investment

1. Location	12-9, Daikyo-cho, Shinjuku-ku, Tokyo 160-0015, JAPAN.
2. Representative	Keiichi Fukuda, CEO
3. Established	November 30, 2015
4. Capital	1,800 million Japanese yen (as of August 31, 2019)
5. Business	Cardiac regenerative medicine using iPSCs
6. Relationship	There is no reporting item applicable to this matter

3. Contents of this investment

1. Amount and ownership ratio of this investment	Not disclosed as unlisted company and not applicable to equity method affiliates.
2. Payment date	August 30, 2019 *Remarks: This announcement is made today as the prospects for a series of funding in Heartseed is confirmed.

4. Future outlook

The impact of this transaction on the business results for the fiscal year ending March 2020 is expected to be minimal.